Edgewise Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the quarterly period ended June 30, 2026, as reported on August 6, 2026.

Key Highlights

  • Shares outstanding: As of July 31, 2026, there were 108,604,129 shares of common stock outstanding.
  • Filer classification: Edgewise Therapeutics is classified as a large accelerated filer, and not a smaller reporting company or emerging growth company.
  • Incorporated in Delaware: The company is incorporated in Delaware with an I.R.S. Employer Identification Number of 82-1725586.
  • Principal office: The company's principal executive offices are located at 1715 38th St., Boulder, CO 80301.
  • Product pipeline: According to the filing, the company's reported product candidates include EDG-7500, EDG-15400, and product candidates from its EDG-003 cardiometabolic discovery program.
  • Filing compliance: The registrant confirmed it has filed all required reports during the preceding 12 months and has submitted all required Interactive Data Files electronically.

Edgewise Therapeutics Q2 2026 Quarterly Report: Key Details

Edgewise Therapeutics, Inc. (Nasdaq Global Select Market: EWTX) submitted its Form 10-Q for the quarterly period ended June 30, 2026. The filing confirmed that as of July 31, 2026, there were 108,604,129 shares of the registrant's common stock outstanding. The company's common stock carries a par value of $0.0001 per share and trades on the Nasdaq Global Select Market under the ticker symbol EWTX.

According to the filing, Edgewise Therapeutics describes itself as focused on cardiovascular and cardiometabolic diseases, with product candidates including EDG-7500, EDG-15400, and candidates from its EDG-003 cardiometabolic discovery program. The filing notes the company's strategy centers on utilizing "our proprietary drug discovery platform to develop a pipeline of product candidates to address cardiovascular and cardiometabolic diseases," as stated in the forward-looking statements section. Those statements are the company's own and are subject to its cautionary language regarding risks and uncertainties.

The quarterly report covers financial statements, management's discussion and analysis, market risk disclosures, and controls and procedures in Part I, followed by legal proceedings, risk factors, and other information in Part II. The filing does not identify any shell company status, with the registrant indicating it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

What Was Disclosed

Edgewise Therapeutics filed a Form 10-Q for the period ended June 30, 2026, disclosing 108,604,129 shares outstanding as of July 31, 2026, its large accelerated filer status, and details of its cardiovascular and cardiometabolic product pipeline.